FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Bin Lee, ARY
   Wong, SY
   Chai, LYA
   Lee, SC
   Lee, MX
   Muthiah, MD
   Tay, SH
   Teo, CB
   Tan, BKJ
   Chan, YH
   Sundar, R
   Soon, YY
AF Bin Lee, Ainsley Ryan Yan
   Wong, Shi Yin
   Chai, Louis Yi Ann
   Lee, Soo Chin
   Lee, Matilda Xinwei
   Muthiah, Mark Dhinesh
   Tay, Sen Hee
   Teo, Chong Boon
   Tan, Benjamin Kye Jyn
   Chan, Yiong Huak
   Sundar, Raghav
   Soon, Yu Yang
TI Efficacy of covid-19 vaccines in immunocompromised patients: systematic
   review and meta-analysis
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Review
ID RENAL-TRANSPLANT RECIPIENTS; MESSENGER-RNA VACCINE; INFLUENZA
   VACCINATION; SARS-COV-2 VACCINATION; BNT162B2 VACCINATION; HUMORAL
   RESPONSE; PUBLICATION BIAS; IMMUNE-RESPONSE; ANTIBODY; HIV
AB OBJECTIVE
   To compare the efficacy of covid-19 vaccines between immunocompromised and immunocompetent people.
   DESIGN
   Systematic review and meta-analysis.
   DATA SOURCES
   PubMed, Embase, Central Register of Controlled Trials, COVID-19 Open Research Dataset Challenge (CORD-19), and WHO covid-19 databases for studies published between 1 December 2020 and 5 November 2021. ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform were searched in November 2021 to identify registered but as yet unpublished or ongoing studies.
   STUDY SELECTION
   Prospective observational studies comparing the efficacy of covid-19 vaccination in immunocompromised and immunocompetent participants.
   METHODS
   A frequentist random effects meta-analysis was used to separately pool relative and absolute risks of seroconversion after the first and second doses of a covid-19 vaccine. Systematic review without meta-analysis of SARS-CoV-2 antibody titre levels was performed after first, second, and third vaccine doses and the seroconversion rate after a third dose. Risk of bias and certainty of evidence were assessed.
   RESULTS
   82 studies were included in the meta-analysis. Of these studies, 77 (94%) used mRNA vaccines, 16 (20%) viral vector vaccines, and 4 (5%) inactivated whole virus vaccines. 63 studies were assessed to be at low risk of bias and 19 at moderate risk of bias. After one vaccine dose, seroconversion was about half as likely in patients with haematological cancers (risk ratio 0.40, 95% confidence interval 0.32 to 0.50, I-2=80%; absolute risk 0.29, 95% confidence interval 0.20 to 0.40, I-2=89%), immune mediated inflammatory disorders (0.53, 0.39 to 0.71, I-2=89%; 0.29, 0.11 to 0.58, I-2=97%), and solid cancers (0.55, 0.46 to 0.65, I-2=78%; 0.44, 0.36 to 0.53, I-2=84%) compared with immunocompetent controls, whereas organ transplant recipients were 16 times less likely to seroconvert (0.06, 0.04 to 0.09, I-2=0%; 0.06, 0.04 to 0.08, I-2=0%). After a second dose, seroconversion remained least likely in transplant recipients (0.39, 0.32 to 0.46, I-2=92%; 0.35, 0.26 to 0.46), with only a third achieving seroconversion. Seroconversion was increasingly likely in patients with haematological cancers (0.63, 0.57 to 0.69, I-2=88%; 0.62, 0.54 to 0.70, I-2=90%), immune mediated inflammatory disorders (0.75, 0.69 to 0.82, I-2=92%; 0.77, 0.66 to 0.85, I-2=93%), and solid cancers (0.90, 0.88 to 0.93, I-2=51%; 0.89, 0.86 to 0.91, I-2=49%). Seroconversion was similar between people with HIV and immunocompetent controls (1.00, 0.98 to 1.01, I-2=0%; 0.97, 0.83 to 1.00, I-2=89%). Systematic review of 11 studies showed that a third dose of a covid-19 mRNA vaccine was associated with seroconversion among vaccine non-responders with solid cancers, haematological cancers, and immune mediated inflammatory disorders, although response was variable in transplant recipients and inadequately studied in people with HIV and those receiving nonmRNA vaccines.
   CONCLUSION
   Seroconversion rates after covid-19 vaccination were significantly lower in immunocompromised patients, especially organ transplant recipients. A second dose was associated with consistently improved seroconversion across all patient groups, albeit at a lower magnitude for organ transplant recipients. Targeted interventions for immunocompromised patients, including a third (booster) dose, should be performed.
C1 [Bin Lee, Ainsley Ryan Yan; Wong, Shi Yin; Teo, Chong Boon; Tan, Benjamin Kye Jyn] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore.
   [Chai, Louis Yi Ann] Natl Univ Hlth Syst, Div Infect Dis, Singapore, Singapore.
   [Chai, Louis Yi Ann; Sundar, Raghav; Soon, Yu Yang] Natl Univ Singapore, Dept Med, Yong Loo Lin Sch Med, Singapore, Singapore.
   [Chai, Louis Yi Ann] Natl Univ Singapore, Synthet Biol Clin & Technol Innovat, Singapore, Singapore.
   [Chai, Louis Yi Ann] Natl Univ Canc Inst, Singapore, Singapore.
   [Lee, Soo Chin; Lee, Matilda Xinwei; Sundar, Raghav] Natl Univ Singapore Hosp, Natl Univ Canc Inst, Dept Haematol Oncol, Singapore 119228, Singapore.
   [Lee, Soo Chin] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore.
   [Muthiah, Mark Dhinesh] Natl Univ Hlth Syst, Dept Gastroenterol & ITepatol, Singapore, Singapore.
   [Muthiah, Mark Dhinesh] Natl Univ, Ctr Organ Transplantat, Singapore, Singapore.
   [Tay, Sen Hee] Natl Univ Singapore Hosp, Dept Med, Div Rheumatol, Singapore, Singapore.
   [Chan, Yiong Huak] Natl Univ Singapore, Yong Loo Lin Sch Med, Biostat Unit, Singapore, Singapore.
   [Sundar, Raghav] Duke NUS Med Sch, Canc & Stem Cell Biol Program, Singapore, Singapore.
   [Sundar, Raghav] Natl Univ Singapore, N1 Inst Hlth, Singapore, Singapore.
   [Sundar, Raghav] Singapore Gastr Canc Consortium, Singapore, Singapore.
   [Soon, Yu Yang] Natl Univ Canc Inst, Dept Radiat Oncol, Singapore, Singapore.
RP Sundar, R (corresponding author), Natl Univ Singapore, Dept Med, Yong Loo Lin Sch Med, Singapore, Singapore.; Sundar, R (corresponding author), Natl Univ Singapore Hosp, Natl Univ Canc Inst, Dept Haematol Oncol, Singapore 119228, Singapore.; Sundar, R (corresponding author), Duke NUS Med Sch, Canc & Stem Cell Biol Program, Singapore, Singapore.; Sundar, R (corresponding author), Natl Univ Singapore, N1 Inst Hlth, Singapore, Singapore.; Sundar, R (corresponding author), Singapore Gastr Canc Consortium, Singapore, Singapore.
EM mdcragh@nus.edu.sg
OI Tan, Benjamin Kye Jyn/0000-0002-9411-6164
CR Achiron A, 2021, J NEUROIMMUNOL, V361, DOI 10.1016/j.jneuroim.2021.577746
   Achiron A, 2021, THER ADV NEUROL DISO, V14, DOI 10.1177/17562864211012835
   Agbarya A, 2021, CANCERS, V13, DOI 10.3390/cancers13164191
   Al Samaraee A, 2020, BRIT J HOSP MED, V81, DOI 10.12968/hmed.2020.0191
   Ali A, 2021, VACCINE, V39, P6111, DOI 10.1016/j.vaccine.2021.08.078
   Ali MAM, 2021, TRENDS CARDIOVAS MED, V31, P143, DOI 10.1016/j.tcm.2020.12.004
   American Society of Transplantation International Society for Heart and Lung Transplantation, 2021, JOINT STAT VACC EFF
   Anema A, 2008, HIV MED, V9, P57, DOI 10.1111/j.1468-1293.2008.00515.x
   Apostolidis SA, 2021, NAT MED, V27, P1990, DOI 10.1038/s41591-021-01507-2
   Barriere J, 2021, ANN ONCOL, V32, P1053, DOI 10.1016/j.annonc.2021.04.019
   Beck CR, 2012, J INFECT DIS, V206, P1250, DOI 10.1093/infdis/jis487
   Benotmane I, 2021, JAMA-J AM MED ASSOC, V326, P1063, DOI 10.1001/jama.2021.12339
   Berlin DA, 2020, NEW ENGL J MED, V383, P2451, DOI 10.1056/NEJMcp2009575
   Bertrand D, 2021, KIDNEY INT, V100, P1337, DOI 10.1016/j.kint.2021.09.014
   Bitoun S, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01183-2
   Boekel L, 2021, LANCET RHEUMATOL, V3, pE778, DOI 10.1016/S2665-9913(21)00222-8
   Canti L, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01190-3
   Catherine FX, 2017, HUM VACC IMMUNOTHER, V13, P1304, DOI 10.1080/21645515.2016.1277844
   Centers for Disease Control and Prevention, COV 19 VACC MOD SEV
   Chavarot N, 2021, AM J TRANSPLANT, V21, P4043, DOI 10.1111/ajt.16814
   Chong PP, 2018, CLIN INFECT DIS, V66, P1802, DOI 10.1093/cid/cix1081
   Chowdhury O, 2021, BRIT J HAEMATOL, V194, P1010, DOI 10.1111/bjh.17644
   Couch Robert B., 1997, American Journal of Medicine, V102, P2, DOI 10.1016/S0002-9343(97)00003-X
   Crespo M, 2022, AM J TRANSPLANT, V22, P786, DOI 10.1111/ajt.16854
   Curtis JR, 2021, ARTHRITIS RHEUMATOL, V73, pE60, DOI 10.1002/art.41928
   D'Offizi G, 2022, LIVER INT, V42, P180, DOI 10.1111/liv.15089
   Danthu C, 2021, J AM SOC NEPHROL, V32, P2154, DOI 10.1681/ASN.2021040490
   Debska-Slizien A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101165
   Deepak P, 2021, ANN INTERN MED, V174, P1572, DOI 10.7326/M21-1757
   Del Bello A, 2022, AM J TRANSPLANT, V22, P322, DOI 10.1111/ajt.16775
   Di Noia V, 2021, CLIN CANCER RES, V27, P6815, DOI 10.1158/1078-0432.CCR-21-2439
   Doria-Rose N, 2021, NEW ENGL J MED, V384, P2259, DOI 10.1056/NEJMc2103916
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Earle KA, 2021, VACCINE, V39, P4423, DOI 10.1016/j.vaccine.2021.05.063
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eliakim-Raz N, 2021, JAMA ONCOL, V7, P1716, DOI 10.1001/jamaoncol.2021.4390
   Fan YJ, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9090989
   Fathizadeh H, 2021, INT J BIOL MACROMOL, V188, P740, DOI 10.1016/j.ijbiomac.2021.08.076
   Furer V, 2021, ANN RHEUM DIS, V80, P1330, DOI 10.1136/annrheumdis-2021-220647
   Garcia-Beltran WF, 2021, CELL, V184, P476, DOI 10.1016/j.cell.2020.12.015
   Gavriatopoulou M, 2021, BLOOD ADV, V5, P4398, DOI 10.1182/bloodadvances.2021005444
   Gavriatopoulou M, 2021, CLIN EXP MED, DOI 10.1007/s10238-021-00746-4
   Geisen UM, 2021, ANN RHEUM DIS, V80, P1306, DOI 10.1136/annrheumdis-2021-220272
   Ghione P, 2021, BLOOD, V138, P811, DOI 10.1182/blood.2021012443
   Goshen-Lago T, 2021, JAMA ONCOL, V7, P1507, DOI 10.1001/jamaoncol.2021.2675
   Greenberger LM, 2021, CANCER CELL, V39, P1297, DOI 10.1016/j.ccell.2021.09.001
   Grinshpun A, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100283
   Grupper A, 2021, CLIN TRANSPLANT, V35, DOI 10.1111/ctr.14478
   Grupper A, 2021, AM J TRANSPLANT, V21, P2719, DOI 10.1111/ajt.16615
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Haberman RH, 2021, ANN RHEUM DIS, V80, P1339, DOI 10.1136/annrheumdis-2021-220597
   Hagin D, 2021, J ALLERGY CLIN IMMUN, V148, P739, DOI 10.1016/j.jaci.2021.05.029
   Hall VG, 2021, NEW ENGL J MED, V385, P1244, DOI 10.1056/NEJMc2111462
   Herishanu Y, 2021, BLOOD, V137, P3165, DOI 10.1182/blood.2021011568
   Tzarfati KH, 2021, AM J HEMATOL, V96, P1195, DOI 10.1002/ajh.26284
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hod T, 2021, TRANSPLANTATION, V105, pE234, DOI 10.1097/TP.0000000000003889
   Iacono D, 2021, J GERIATR ONCOL, V12, P1253, DOI 10.1016/j.jgo.2021.06.002
   Izmirly PM, 2022, ARTHRITIS RHEUMATOL, V74, P284, DOI 10.1002/art.41937
   Jedicke N, 2022, HIV MED, V23, P558, DOI 10.1111/hiv.13202
   Jin PF, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00481-y
   Kantauskaite M, 2022, AM J TRANSPLANT, V22, P634, DOI 10.1111/ajt.16851
   Kennedy NA, 2021, GUT, V70, P1884, DOI 10.1136/gutjnl-2021-324789
   Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8
   Korth J, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13050756
   Lee JH, 2020, VACCINE, V38, P3995, DOI 10.1016/j.vaccine.2020.04.022
   Levy I, 2021, CLIN MICROBIOL INFEC, V27, P1851, DOI 10.1016/j.cmi.2021.07.031
   Ligumsky H, 2022, JNCI-J NATL CANCER I, V114, P203, DOI 10.1093/jnci/djab174
   Lim SH, 2021, LANCET HAEMATOL, V8, pE542, DOI 10.1016/S2352-3026(21)00199-X
   Linardou H, 2021, CANCERS, V13, DOI 10.3390/cancers13184621
   Lindemann M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101075
   Liontos M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101148
   Liontos M, 2022, PROSTATE CANCER P D, V25, P117, DOI 10.1038/s41391-021-00455-9
   Livingston Edward H, 2021, JAMA, V325, P898, DOI 10.1001/jama.2021.1375
   Madan A, 2020, CANCER MED-US, V9, P9205, DOI 10.1002/cam4.3534
   Madhi SA, 2021, LANCET HIV, V8, pE568, DOI 10.1016/S2352-3018(21)00157-0
   Mahil SK, 2021, LANCET RHEUMATOL, V3, pE627, DOI 10.1016/S2665-9913(21)00212-5
   Malard F, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00534-z
   Manuel O, 2019, CLIN TRANSPLANT, V33, DOI 10.1111/ctr.13511
   Marasco V, 2022, BRIT J HAEMATOL, V196, P548, DOI 10.1111/bjh.17877
   Marinaki S, 2021, AM J TRANSPLANT, V21, P2913, DOI 10.1111/ajt.16607
   Massarweh A, 2021, JAMA ONCOL, V7, P1133, DOI 10.1001/jamaoncol.2021.2155
   Mazzola A, 2022, CLIN INFECT DIS, V74, P1093, DOI 10.1093/cid/ciab580
   McInnes IB, 2021, NAT REV IMMUNOL, V21, P680, DOI 10.1038/s41577-021-00603-1
   Medeiros-Ribeiro AC, 2021, NAT MED, V27, P1744, DOI 10.1038/s41591-021-01469-5
   Miele M, 2021, AM J TRANSPLANT, V21, P2919, DOI 10.1111/ajt.16702
   Mohammed AH, 2020, AIDS REV, V22, P151, DOI 10.24875/AIDSRev.20000052
   Monin L, 2021, LANCET ONCOL, V22, P765, DOI 10.1016/S1470-2045(21)00213-8
   Mrak D, 2021, ANN RHEUM DIS, V80, P1345, DOI 10.1136/annrheumdis-2021-220781
   Narasimhan M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070708
   Page MJ, 2021, PLOS MED, V18, DOI [10.1371/journal.pmed.1003583, 10.1016/j.ijsu.2021.105906]
   Palich R, 2021, Ann Oncol, V32, P1294, DOI 10.1016/j.annonc.2021.06.018
   Palich R, 2021, ANN ONCOL, V32, P1051, DOI 10.1016/j.annonc.2021.04.020
   Parry H, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00528-x
   Peeters M, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100274
   Peled Y, 2022, J HEART LUNG TRANSPL, V41, P148, DOI 10.1016/j.healun.2021.08.010
   Peled Y, 2021, J HEART LUNG TRANSPL, V40, P759, DOI 10.1016/j.healun.2021.04.003
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Peters JL, 2007, STAT MED, V26, P4544, DOI 10.1002/sim.2889
   Pimpinelli F, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01090-6
   Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577
   Pregliasco F, 1996, VACCINE, V14, P267, DOI 10.1016/0264-410X(95)00209-J
   Prendecki M, 2021, LANCET, V398, P1482, DOI 10.1016/S0140-6736(21)02096-1
   Prendecki M, 2021, ANN RHEUM DIS, V80, P1322, DOI 10.1136/annrheumdis-2021-220626
   Rabinowich L, 2021, J HEPATOL, V75, P435, DOI 10.1016/j.jhep.2021.04.020
   Rahav G, 2021, ECLINICALMEDICINE, V41, DOI 10.1016/j.eclinm.2021.101158
   Rashidi-Alavijeh J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070738
   Reuken PA, 2022, J CROHNS COLITIS, V16, P251, DOI 10.1093/ecco-jcc/jjab147
   Rincon-Arevalo H, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abj1031
   Roifman CM, 2021, LYMPHOSIGN J, V8, P37, DOI 10.14785//lymphosign-2021-0020
   Rubbert-Roth A, 2021, LANCET RHEUMATOL, V3, pE470, DOI 10.1016/S2665-9913(21)00186-7
   Ruether DF, 2022, CLIN GASTROENTEROL H, V20, P162, DOI 10.1016/j.cgh.2021.09.003
   Sattler A, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI150175
   Schmidt T, 2021, AM J TRANSPLANT, V21, P3990, DOI 10.1111/ajt.16818
   Schmiedeberg K, 2022, LANCET RHEUMATOL, V4, pE11, DOI 10.1016/S2665-9913(21)00328-3
   Schramm R, 2021, CLIN RES CARDIOL, V110, P1142, DOI 10.1007/s00392-021-01880-5
   Schrezenmeier E, 2021, J AM SOC NEPHROL, V32, P3027, DOI 10.1681/ASN.2021070966
   Seyahi E, 2021, RHEUMATOL INT, V41, P1429, DOI 10.1007/s00296-021-04910-7
   Shem-Tov N, 2022, BRIT J HAEMATOL, V196, P884, DOI 10.1111/bjh.17918
   Sherman AC, 2021, CLIN INFECT DIS, DOI 10.1093/cid/ciab930
   Shinjo SK, 2021, RHEUMATOLOGY, DOI 10.1093/rheumatology/keab773
   Shmueli ES, 2021, EUR J CANCER, V157, P124, DOI 10.1016/j.ejca.2021.08.007
   Shroff RT, 2021, NAT MED, V27, P2002, DOI 10.1038/s41591-021-01542-z
   Silva-Cayetano A, 2021, MED-CAMBRIDGE, V2, P243, DOI 10.1016/j.medj.2020.12.006
   Simon D, 2021, ANN RHEUM DIS, V80, P1312, DOI 10.1136/annrheumdis-2021-220461
   Ssentongo P, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85359-3
   Stampfer SD, 2021, LEUKEMIA, V35, P3534, DOI 10.1038/s41375-021-01354-7
   Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
   Stumpf J, 2021, LANCET REG HEALTH-EU, V9, DOI 10.1016/j.lanepe.2021.100178
   Terpos E, 2021, CANCERS, V13, DOI 10.3390/cancers13174480
   Terpos E, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01099-x
   US Food and Drug Administration, 2021, COR COVID 19 UPD FDA
   Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1
   Westhoff TH, 2021, KIDNEY INT, V100, P1135, DOI 10.1016/j.kint.2021.09.001
   Westra J, 2014, CLIN EXP IMMUNOL, V178, P40, DOI 10.1111/cei.12390
   Wise J, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2160
   Woldemeskel BA, 2022, CLIN INFECT DIS, V74, P1268, DOI 10.1093/cid/ciab648
   Wong SY, 2021, GASTROENTEROLOGY, V161, P715, DOI 10.1053/j.gastro.2021.04.025
   Yi Stephanie G, 2021, Transplantation, V105, pe72, DOI 10.1097/TP.0000000000003764
   Zagouri F, 2021, BREAST, V60, P58, DOI 10.1016/j.breast.2021.08.017
   Zbinden D, 2014, IMMUNOTHERAPY-UK, V6, P131, DOI [10.2217/IMT.13.171, 10.2217/imt.13.171]
   Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344
NR 143
TC 3
Z9 3
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0959-535X
EI 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD MAR 2
PY 2022
VL 376
AR e068632
DI 10.1136/bmj-2021-068632
PG 16
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA ZX8XR
UT WOS:000772178100006
PM 35236664
OA Green Published, Green Submitted, hybrid
DA 2022-05-16
ER

EF